ERBB3 and breast cancer: For example, in a clinical trial evaluating seribantumab (MM-121) in combination with exemestane in patients with ER/PR+, HER2-negative metastatic BC, the expression of prespecified biomarkers (HRG, betacellulin, EGFR, ErbB2, and ErbB3) was analyzed using RT-PCR.